Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...

FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...

The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

AstraZeneca announced it has received FDA approval for the self-administration of benralizumab in a prefilled, single-use auto-injector pen for patients with severe eosinophilic asthma, according to a ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

AstraZeneca, global, science-led biopharmaceutical company, announced that its Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult ...